Citations 23
Embolization of Brain Arteriovenous Malformations With Versus Without Onyx Before Stereotactic Radiosurgery
Chen, Ching‐Jen , Ding, Dale , Lee, Cheng‐Chia , Kearns, Kathryn N. , Pomeraniec, I. Jonathan , Cifarelli, Christopher P. , Arsanious, David, Liščák, Roman , Hanuška, Jaromír, Woo, Shiao Y. , Ironside, Natasha , Warnick, Ronald E. , Mathieu, David , Mureb, Monica , Benjamin, Carolina , Feliciano, Caleb , Rodríguez‐Mercado, Rafael, Cockroft, Kevin M. , Simon, Scott D. , Mackley, Heath B., Zammar, Samer G. , Patel, Neel, Padmanaban, Varun , Beatson, Nathan, Saylany, Anissa , Lee, John, Sheehan, Jason P. , May, Jaromír , Ding, Dale , Mathieu, David , Chen, Ching-Jen , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Kondziolka, Douglas , Lee, John
Neurosurgery | July 23, 2020 | Volume: 88 | Issue: 2 | Pages: 366-374
Abstract BACKGROUND Embolization of brain arteriovenous malformations (AVMs) using ethylene-vinyl alcohol copolymer (Onyx) embolization may influence the treatment effects of stereotactic radiosurgery (SRS) differently than other embolysates. OBJECTIVE To compare the outcomes of pre-SRS AVM embolization with vs without Onyx through a multicenter, retrospective matched cohort study. METHODS We retrospectively reviewed International Radiosurgery Research Foundation AVM databases from 1987 to 2018. Embolized AVMs treated with SRS were selected and categorized based on embolysate usage into Onyx embolization (OE + SRS) or non-Onyx embolization (NOE + SRS) cohorts. The 2 cohorts were matched in a 1:1 ratio using de novo AVM features for comparative analysis of outcomes. RESULTS The matched cohorts each comprised 45 patients. Crude AVM obliteration rates were similar between the matched OE + SRS vs NOE + SRS cohorts (47% vs 51%; odds ratio [OR] = 0.837, P = .673). Cumulative probabilities of obliteration were also similar between the OE + SRS vs NOE + SRS cohorts (subhazard ratio = 0.992, P = .980). Rates of post-SRS hemorrhage, all-cause mortality, radiation-induced changes, cyst formation, and embolization-associated complications were similar between the matched cohorts. Sensitivity analysis for AVMs in the OE + SRS cohort embolized with Onyx alone revealed a higher rate of asymptomatic embolization-associated complications in this subgroup compared to the NOE + SRS cohort (36% vs 15%; OR = 3.297, P = .034), but the symptomatic complication rates were similar. CONCLUSION Nidal embolization using Onyx does not appear to differentially impact the outcomes of AVM SRS compared with non-Onyx embolysates. The embolic agent selected for pre-SRS AVM embolization should reflect both the experience of the neurointerventionalist and target of endovascular intervention.
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
Rusthoven, Chad G. , Yamamoto, Masaaki , Smith, Derek , Serizawa, Toru , Yomo, Shoji , Aiyama, Hitoshi, Shuto, Takashi , Akabane, Atsuya , Sato, Yasunori , Niranjan, Ajay , Faramand, Andrew , Lunsford, L. Dade , McInerney, James , Tuanquin, Leonard, Chiang, Veronica , Singh, Charu , Mathieu, David , Touchette, Charles, Lee, Cheng‐Chia , Aizer, Ayal A. , Cagney, Daniel , Kondziolka, Douglas , Bernstein, Kenneth , Silverman, Joshua S. , Grills, Inga S., Yuan, Justin C. , Sheehan, Jason P. , Cordeiro, Diogo , Nosaki, Kename, Seto, T., Deibert, Christopher P., Day, Samuel E., Halasz, Lia M. , Warnick, Ronald E. , Palmer, Joshua D. , Attia, Albert, Li, Benjamin , Cifarelli, Christopher P. , Brown, Paul D. , Vargo, John A. , Kessel, Kerstin A. , Rieken, Stefan , Patel, Samir , Gückenberger, Matthias , Andratschke, Nicolaus , Kavanagh, Brian D. , Palmer, Joshua D , Mathieu, David , Andratschke, Nicolaus , Kondziolka, Douglas , Bernhardt, Denise , Gao, Dexiang , Higuchi, Yoshinori , Zacharia, Brad E. , Yu, James B. , Braunstein, Steve , Yang, Huai‐Che , Chan, Michael David , Siddiqui, Zaid Ali , Verma, Vivek , Trifiletti, Daniel M. , Combs, Stephanie Elisabeth , Robin, Tyler P.
JAMA Oncology | June 4, 2020 | Volume: 6 | Issue: 7 | Pages: 1028
Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK
Liu, Xiaona , Chhipa, Rishi Raj , Pooya, Shabnam, Wortman, Matthew D. , Yachyshin, Sara, Chow, Lionel M.L. , Zhou, Xuan , McPherson, Christopher, Warnick, Ronald E. , Kendler, Ady , Poels, Jeroen, Norga, Koen , Viollet, Benoı̂t , Grabowski, Gregory A. , Dasgupta, Biplab , Kumar, Ashish , Sun, Ying Hao , Quinn, Brian , Giri, Shailendra , Viollet, Benoit
Proceedings of the National Academy of Sciences | January 13, 2014 | Volume: 111 | Issue: 4 | Pages: No page available
Significance Cancer cells reprogram their metabolism for optimal growth and survival. AMPK-activated protein kinase (AMPK) is a key energy sensor that controls many metabolic pathways including metabolic reprogramming. However, its role in cancer is poorly understood. Some studies claim that it has a tumor suppressor role while others show its protumor role. Two AMPK-activating compounds (including metformin, now in many clinical trials) are widely used to suppress cancer cell proliferation. We found that AMPK is abundantly expressed in high-grade gliomas and, in contrast to popular belief, these two AMPK activators suppressed glioma cell proliferation through unique AMPK-independent mechanisms.